Combined stereotactic radiation therapy and immunotherapy for metastatic uveal melanoma.

Front Oncol · 2025 · PMC12094999 · PMID 40406270

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

showed a trendp=0.12not close (p > 0.1)

combination therapy) showed a trend toward improved outcomes after combination therapy (HR: 0.21, 95% CI: 0.03–1.50, p=0.12), but that did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.